Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

NCT05917106 · tracked via the Priya Life Science China tracker

Sponsor

Jinling Hospital, China

Phase

Observational

Started

2022-12-26

Last updated

2025-12-11

Condition(s) studied

CarcinomaRenal Cell CarcinomaRCCKidney NeoplasmsKidney Cancer

Study summary

To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Newly diagnosed renal cell carcinoma * Without any treatment * Agree and accept radical surgical treatment * Signed written informed consent * ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1 * Follow up protocol and related procedures Exclusion Criteria: * Had other cancers * Had received any antitumor therapy before * Known or suspected active autoimmune disease * Informed consent is not possible due to medical or psychiatric problems * Have clinical symptoms or diseases of the heart that are not well controlled * Patients judged by the investigators to be unsuitable for inclusion in this study

Primary outcome measure(s)

To explore the predictive effect of ctDNA methylomics on the prognosis and medication guidance of renal carcinoma. — 5 years
To explore the advance time of ctDNA methylomics in monitoring postoperative recurrence of renal cancer compared with imaging. — 5 years
The molecular mechanism of renal cancer recurrence was analyzed with baseline tissue and circulating methylation profiles. — 5 years
A renal cancer recurrence risk model was established based on clinical information, molecular risk factors and ctDNA methylomics — 5 years

Trial sites (1)

Facility	City	Region	Status
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China	Nanjing	Jiangsu	Recruiting

More Jinling Hospital, China trials in China

Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery Recruiting

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy Recruiting

Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction Recruiting

A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma Recruiting

Comparison of Two Stapled Antimesenteric Anastomosis for CD: a Randomized Control Trial Study Recruiting

Other trials for the same condition

Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation of RCC With T1 Stage Recruiting

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. Active, not recruiting

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy Recruiting

The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study Starting soon

Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05917106 on ClinicalTrials.gov ↗ ← All trials in China